You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

r/r NHL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

Completed
Has Results
  • Non-Hodgkin's Lymphoma, Relapsed
  • +8 more
  • PBCAR20A
  • +2 more
  • Duarte, California
  • +4 more
Jan 4, 2023

Non Hodgkin's Lymphoma Trial in Beijing (Allogenic CD19-CAR-?dT cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non Hodgkin's Lymphoma
  • Allogenic CD19-CAR-γδT cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Jan 31, 2023

NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

Recruiting
  • NHL
  • NHL, Relapsed, Adult
  • Birmingham, Alabama
  • +4 more
May 31, 2023

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell Trial (ONO-7018)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • (no location specified)
Aug 23, 2022

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • regimen with BTK inhibitor +Anti-CD19 CAR T cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Non-Hodgkin Lymphoma Trial in Dallas (Focal radiation therapy (RT))

Recruiting
  • Non-Hodgkin Lymphoma
  • Focal radiation therapy (RT)
  • Dallas, Texas
    UT Southwestern Medical Center
Jul 8, 2022

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in United States (PBCAR0191, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-Hodgkin Lymphoma
  • B-cell Acute Lymphoblastic Leukemia
  • PBCAR0191
  • +2 more
  • Duarte, California
  • +9 more
Apr 18, 2022

LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
    • (no location specified)
    Sep 19, 2023

    Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors Trial in Beijing (Chidamide, Decitabine, Immune checkpoint

    Recruiting
    • Relapsed/Refractory Non-Hodgkin Lymphoma
    • Advanced Solid Tumors
    • Beijing, Beijing, China
      Biotherapeutic Department, Chinese PLA General Hospital
    Apr 8, 2022

    Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

    Not yet recruiting
    • Advanced Malignancies
    • 1A46 Drug Substance
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Aug 4, 2023

    Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • UCD19 CAR T Cells
    • Aurora, Colorado
      University of Colorado Hospital
    Sep 1, 2022

    Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

    Not yet recruiting
    • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
    • (no location specified)
    Mar 23, 2023

    Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

    Not yet recruiting
    • Non Hodgkin's Lymphoma
    • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
    • +2 more
    • Beijing, China
    • +2 more
    Aug 23, 2023

    Non-Hodgkin Lymphoma Trial in Aurora (CD19x22 CAR T Cells)

    Active, not recruiting
    • Non-Hodgkin Lymphoma
    • CD19x22 CAR T Cells
    • Aurora, Colorado
      University of Colorado Hospital
    Sep 1, 2022

    B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))

    Active, not recruiting
    • B-Cell Lymphoma
    • Non-Hodgkin Lymphoma
    • Birmingham, Alabama
    • +23 more
    Dec 2, 2022

    Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

    Recruiting
    • Non-hodgkin Lymphoma,B Cell
    • Autologous CD19-STAR-T cell
    • +2 more
    • Beijing, Beijing, China
    • +1 more
    Nov 21, 2022

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in Hefei, Nanjing, Beijing (LUCAR-20S CAR-T

    Terminated
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • LUCAR-20S CAR-T cells
    • Hefei, Anhui, China
    • +2 more
    Dec 17, 2021

    Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in Changsha, Suzhou (U16)

    Recruiting
    • Relapsed or Refractory Non-Hodgkin's Lymphoma
    • Changsha, Hunan, China
    • +1 more
    Mar 13, 2023

    NHL, DLBCL - Diffuse Large B Cell Lymphoma Trial in Netherlands (ARI-0001, Axi-cel)

    Recruiting
    • NHL
    • DLBCL - Diffuse Large B Cell Lymphoma
    • Amsterdam, Netherlands
    • +6 more
    Nov 30, 2022

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in Hefei, Nanjing, Beijing (LUCAR-20S CAR-T

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • LUCAR-20S CAR-T cells
    • Beijing, Beijing, China
      Beijing Boren Hospital
    Aug 5, 2021

    Non-Hodgkin's B-cell Lymphoma Trial in Hangzhou (CD19/CD20-directed CAR-T cells)

    Recruiting
    • Non-Hodgkin's B-cell Lymphoma
    • CD19/CD20-directed CAR-T cells
    • Hangzhou, Zhejiang, China
      First Affiliated Hospital of Zhejiang University College of Medi
    Apr 10, 2021

    Non Hodgkin Lymphoma Trial (Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • Liposomal Mitoxantrone Hydrochloride dose level 1
    • +6 more
    • (no location specified)
    Mar 17, 2022

    Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing

    Recruiting
    • Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
    • Decitabine-primed Tandem CD19/CD20 CAR T Cells
    • Decitabine-primed Tandem CAR19/20 engineered T cells
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinese PLA General Hospital
    Mar 24, 2022